SGMS2: A Potential Drug Target and Biomarker (G166929)

Target Name: SGMS2

NCBI ID: G166929

SGMS2

SGMS2: A Potential Drug Target and Biomarker

Sangre Graciosa de la Obra Social (SGOS) is a family of proteins that are expressed in various tissues of the human body, including the brain, heart, and pancreas. SGOS2 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SGOS2 is a transmembrane protein that is characterized by its unique structure and various post-translational modifications. SGOS2 is composed of a cytoplasmic tail and a transmembrane region that is involved in various signaling pathways. The cytoplasmic tail of SGOS2 is composed of a unique domain that is known as the N-terminal hypervariable region (HVR1) and is involved in the formation of inclusion complexes with other proteins.

SGOS2 has been shown to play a role in various cellular processes, including cell adhesion, migration, and the regulation of ion channels. SGOS2 has also been shown to be involved in the regulation of cell death, which is a crucial process in the development and progression of many diseases.

One of the key features of SGOS2 is its ability to interact with various signaling pathways and proteins. For example, SGOS2 has been shown to interact with the protein p53, which is a well-known tumor suppressor protein that plays a critical role in the regulation of cell death. SGOS2 has also been shown to interact with the protein NF-kappa-B, which is involved in the regulation of inflammation and immune responses.

SGOS2 has also been shown to be involved in the regulation of cellular signaling pathways that are involved in the development and progression of many diseases, including cancer. For example, SGOS2 has been shown to be involved in the regulation of the signaling pathway that is responsible for the development of neuroblastoma, which is a type of cancer that develops from neural stem cells.

In addition to its potential role in the regulation of cellular signaling pathways, SGOS2 has also been shown to be involved in the regulation of cellular processes that are important for the development and maintenance of tissues. For example, SGOS2 has been shown to be involved in the regulation of cell migration, which is an essential process for the development and maintenance of tissues.

SGOS2 has also been shown to play a role in the regulation of cellular processes that are important for the development and maintenance of the immune system. For example, SGOS2 has been shown to be involved in the regulation of the development and function of T cells, which are a critical part of the immune system.

SGOS2 has also been shown to be involved in the regulation of cellular processes that are important for the development and maintenance of tissues. For example, SGOS2 has been shown to be involved in the regulation of cell adhesion, which is an essential process for the development and maintenance of tissues.

In conclusion, SGOS2 is a protein that has been shown to play a role in various cellular processes that are important for the development and maintenance of tissues. As a potential drug target and biomarker, SGOS2 is a promising target for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of SGOS2 in the regulation of cellular processes and to develop effective treatments for diseases that are caused by its dysfunction.

Protein Name: Sphingomyelin Synthase 2

Functions: Sphingomyelin synthase that primarily contributes to sphingomyelin synthesis and homeostasis at the plasma membrane. Catalyzes the reversible transfer of phosphocholine moiety in sphingomyelin biosynthesis: in the forward reaction transfers phosphocholine head group of phosphatidylcholine (PC) on to ceramide (CER) to form ceramide phosphocholine (sphingomyelin, SM) and diacylglycerol (DAG) as by-product, and in the reverse reaction transfers phosphocholine from SM to DAG to form PC and CER. The direction of the reaction appears to depend on the levels of CER and DAG in the plasma membrane (PubMed:14685263, PubMed:17449912, PubMed:17982138, PubMed:18370930). Does not use free phosphorylcholine or CDP-choline as donors (PubMed:14685263). Can also transfer phosphoethanolamine head group of phosphatidylethanolamine (PE) on to ceramide (CER) to form ceramide phosphoethanolamine (CPE) (PubMed:19454763). Regulates receptor-mediated signal transduction via mitogenic DAG and proapoptotic CER, as well as via SM, a structural component of membrane rafts that serve as platforms for signal transduction and protein sorting (PubMed:17449912, PubMed:17982138). To a lesser extent, plays a role in secretory transport via regulation of DAG pool at the Golgi apparatus and its downstream effects on PRKD1 (PubMed:18370930, PubMed:21980337). Required for normal bone matrix mineralization (PubMed:30779713)

The "SGMS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SGMS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets